354 related articles for article (PubMed ID: 16983521)
1. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effective analysis of rotation from sustained-release morphine tablet to transdermal fentanyl of matrix type or sustained-release oxycodone tablet].
Ise Y; Wako T; Miura Y; Katayama S; Shimizu H
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2599-603. PubMed ID: 20009462
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
6. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
8. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
9. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
12. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.
Weschules DJ; Bain KT; Reifsnyder J; McMath JA; Kupperman DE; Gallagher RM; Hauck WW; Knowlton CH
Pain Med; 2006; 7(4):320-9. PubMed ID: 16898943
[TBL] [Abstract][Full Text] [Related]
13. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine.
Radbruch L; Lehmann K; Gockel HH; Neighbors D; Nuyts G
Eur J Health Econ; 2002 Jun; 3(2):111-9. PubMed ID: 24577592
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
15. Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?
Heidemann AJ; Seaton TL
J Fam Pract; 2001 Oct; 50(10):897. PubMed ID: 11674896
[No Abstract] [Full Text] [Related]
16. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
Neighbors DM; Bell TJ; Wilson J; Dodd SL
J Pain Symptom Manage; 2001 Feb; 21(2):129-43. PubMed ID: 11226764
[TBL] [Abstract][Full Text] [Related]
20. Calculating the cost for drug treatment including the adverse drug reactions treatment cost (primer for fentanyl TTS in Bulgaria).
Petrova GI; Getov IN
Boll Chim Farm; 2002; 141(2):150-3. PubMed ID: 12135164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]